


# PROTEIN ENERGY MALNUTRITION (FAILURE TO THRIVE)

## ALGORITHM



## TABLE OF CONTENTS

[Algorithm](#)

[Target Population](#)

[Definitions and Classification](#)

[Table 1. Normal Rate of Weight Gain](#)

[Table 2. Nutritional Status Assessment](#)

[Initial Evaluation](#)

[Additional Evaluation and Considerations for Consults](#)

[Clinical Management](#)

[Table 3. Micronutrient Indications and Dosing](#)

[Refeeding Syndrome](#)

[Table 4. Enteral Electrolyte Replacement](#)

[Discharge](#)

[Related Documents](#)

Laboratory Studies | Imaging – n/a

Therapeutics – n/a

[Appendix A. Workup for Suspected Inborn Error of Metabolism/Genetics](#)

[Appendix B. Considerations for Cystic Fibrosis/Pancreatic Insufficiency: Understanding the Newborn Screen](#)

[Appendix C. Estimated Energy Needs for Pediatric Patients](#)

[Appendix D. Catch Up Growth Calculations](#)

[Appendix E. ICD 10 Codes](#)

[References](#)

[Clinical Improvement Team](#)

---

## TARGET POPULATION

### Inclusion Criteria

- Children newborn to 21 years of age
- Inpatients admitted for evaluation and treatment of Protein Energy Malnutrition (PEM) or Failure to Thrive (FTT)  
OR
- Patients identified with PEM/FTT during their hospital stay

**Exclusion Criteria**

- Outpatients
- Patients with PEM/FTT secondary to an identified condition (e.g., cancer, identified genetic conditions, or other chronic illness).
- Patients with a suspected or confirmed eating disorder

**DEFINITIONS AND CLASSIFICATION**

**Protein Energy Malnutrition (PEM)** or **Failure to Thrive (FTT)** is defined as an imbalance between nutrient requirement and intake, resulting in cumulative deficits of energy, protein or micronutrients that may negatively affect growth, development and other relevant outcomes [1].

Growth assessment is based on the indicated growth chart in Epic. Select growth chart in Epic based on patient age and any relevant conditions (e.g., Down syndrome, etc.).

**Table 1. Normal Rate of Weight Gain**

Age (months)	Grams/day
0-3	20-30
3-6	15-20
6-9	10-15
9-12	10
12-18	6
18-24	6
24-36	6

**Refeeding (marasmus and Kwashiorkor)**

Severe malnutrition (marasmus) is defined as weight for height (or length) less than -3 Z-score, or less than 70% of the median reference value. Kwashiorkor is defined by the presence of symmetrical edema (edematous malnutrition). Marasmus and Kwashiorkor commonly coexist and a simple unified approach to clinical management can be applied to both [1, 2].

**Table 2. Nutritional Status Assessment**

Method	No malnutrition	Mild malnutrition	Moderate malnutrition	Severe malnutrition
Weight for height percent of median [3]	>90%	80-89%	70-79%	<70%
Weight for height z score* [4]	> -1	-1 to -1.9	-2 to -2.9	< -3
BMI z score* [4]	> -1	-1 to -1.9	-2 to -2.9	<-3
Length/height z score* [4]	Not Applicable	No data but z score* less than -2 suggest stunting	No data but z score* less than -2 suggest stunting	<-3

\*Z scores can be found by placing the cursor on any number on the growth chart in Epic.

## INITIAL EVALUATION

- History and physical exam
- Diagnostic Tests and Studies to be considered in patients admitted for management of malnutrition:
  - CBC with differential and red cell indices (strongly recommended due to the risk of anemia)
  - Comprehensive metabolic panel
  - Baseline magnesium (Mg), phosphorus (Phos), and potassium (K) (in patients at risk for refeeding syndrome)
  - Inflammatory markers such as erythrocytes sedimentation rate (ESR) and C reactive protein (CRP)
  - Iron studies with ferritin (in patients at risk for iron deficiency).
  - Vitamin D (based on the presence of risk factors for deficiency)
  - Celiac screening (based on clues from H&P)
  - Stool examination for fat (if concerned about fat malabsorption based on H&P, or in infants who fail to gain weight despite adequate breast milk or formula intake).

## ADDITIONAL EVALUATION AND CONSIDERATION FOR CONSULTS

- When considering endocrine etiologies for poor growth, please assess linear growth, taking into consideration family history and being small for gestational age. Keep in mind that endocrine causes of FTT seem to be rare even in the selected population of patients referred to pediatric endocrine outpatient clinics. Actually, the majority of patients referred for endocrine evaluation in the setting of PEM had a pure nutritional deficiency [5].
- Refer to [Appendix A](#) for information about when to consider inborn errors of metabolism/genetics [6].
- Refer to [Appendix B](#) for information about Cystic Fibrosis (CF) and pancreatic insufficiency [7].
- Renal tubular acidosis: is a rare cause of PEM, and when suspected it is recommend to use a venous blood gas (VBG ) for determination of serum bicarbonate concentration for the evaluation of a child with PEM who is thought to have a metabolic acidosis [8].
- Consult Nutrition M.D. in all cases of severe malnutrition, edematous malnutrition (Kwashiorkor), and for patients on highly restrictive or unusual diets with possible many micronutrient deficiencies.

## CLINICAL MANAGEMENT

1. Initiate a multidisciplinary approach including but not limited to registered dietitians, social worker, occupational and speech therapists and lactation consultants [9].
2. Inpatient admission is not necessary for all children with FTT [10]. It is indicated for severe malnutrition especially when there is concern about [refeeding syndrome](#), and in complicated social situations [11].
3. Dehydration:
  - Oral hydration is preferred over IV hydration. Use standard pediatric electrolytes solutions. Recommended rate is 5-10 mL/kg/hour for 2-12 hours [1]
  - IV hydration: Refer to [Intravenous Fluid Therapy Clinical Care Guideline](#)
4. Starting and advancing feeding:
  - If the patient is not at risk of [refeeding syndrome](#) it is reasonable to start with age appropriate caloric recommended daily allowance (RDA). Refer to [Appendix C](#).
  - When there is risk of [refeeding syndrome](#) start at 30-50% of caloric RDA and advance slowly by 10-20% per day.

- Patients on oral feed can be transitioned to adlib feeding when tolerating full feed. It is normal for patients recovering from malnutrition to consume over 200 Kcal/kg /day[2]
- Patients with low intake or on tube feeding need to be provided with extra calories for catch up growth after they tolerate full feed.
- Depend on the severity of malnutrition, it may take 2-14 days to be able to initiate catch up growth [11]
- Catch up growth calculations: a rough estimate is to provide RDA calorie for age based on ideal body weight. Fluid requirements: as appropriate for age. For edematous malnutrition, keep fluids at or less than maintenance.
- Calorie goal needs to be adjusted based on how well the patient is gaining weight. Some patients with severe malnutrition may require a high caloric intake to initiate weight gain. Consult with a registered dietician and see [Appendix D](#) for specific calculations for catch up growth.

5. Feeding Modality:

<b>Infants less than 1 year old</b>	<b>Toddlers and children older than 1 year old</b>
<ul style="list-style-type: none"> <li>● Breast milk or formula. Make sure to assess the adequacy of nursing.</li> <li>● Do not concentrate breast milk or formula beyond 24 kcal/oz to avoid the increase in osmolality with associated diarrhea and malabsorption.</li> </ul>	<ul style="list-style-type: none"> <li>● Use nutritional supplements (e.g., Boost, Nutren, etc.)</li> <li>● Start with the standard 1Kcal/1mL concentration.</li> </ul>
<ul style="list-style-type: none"> <li>● Feed every 2-3 hours to prevent hypoglycemia.</li> </ul>	<ul style="list-style-type: none"> <li>● Offer 3 meals and 2-3 snacks on a consistent schedule. Educate parents to avoid “grazing” and constant sipping on fluids.</li> </ul>

- Consult RD if a higher concentration needed (i.e., fluid restriction). Please refer to [CHCO nutrition handouts](#) for concentrating formulas.
- NGT feeding is recommended if the child cannot take 70% of the recommended intake orally [1], but offer the diet orally at each feed first.

6. Monitoring and goals:

- Daily weight: preferred pre-breakfast, post-void
- 3 days calorie count
- For breastfed infants: check weight before and after feeding for at least 24 hours.
- Accepted goal for catch up growth is 150% the average weight gain for age [11] . This may not happen until the outpatient phase.

7. Micronutrients:

- Zinc, Iron and Vitamin D, and Thiamine are common deficiencies in the FTT patients. However, a detailed diet history is essential to diagnose other micronutrient deficiencies.
- For indications and dosing of micronutrients, please refer to [Table 3](#).

Table 3. Micronutrient Indications and Dosing

Medication	Recommended Dose	Indications for Use	Clinical Pearls
<b>Zinc [7]</b>	PO: 1 mg/kg/day elemental zinc divided 1-3 times/day.  Adult dose: 50 mg three times daily.	Over 6 months of age. Zinc supplementation should be initiated empirically for any patient with malnutrition/FTT.	Larger doses may be needed with impaired absorption or excessive loss of zinc in the intestines
<b>Iron (Ferrous Sulfate) [10]</b>	PO: 3-6 mg/kg/day elemental iron divided 1-4 times daily.  Adult dose: 300 mg given 2-4 times daily or 250 mg (extended release) 1-2 times daily	Initiate when ferritin is less than 20 with no inflammation (not for use during acute phase of illness)	Separate from other supplements by 1-2 hours for maximal absorption.
<b>Vitamin D</b>	<p><b>Age 0-10:</b></p> <ul style="list-style-type: none"> <li>• 25(OH)D&lt;10 ng/mL: 2000 IU (4000 IU if obese)</li> <li>• 10 to 20 ng/mL: 1000 IU (2000 IU if obese)</li> <li>• 20 to 30 ng/mL: 400-800 IU (1000 IU if obese)</li> </ul> <p><b>Age 10-18:</b></p> <ul style="list-style-type: none"> <li>• 25(OH)D&lt;10 ng/mL: 4000 IU (8000 IU if obese)</li> <li>• 10 to 20 ng/mL: 2000 IU (4000 IU if obese)</li> <li>• 20 to 30 ng/mL: 800 IU (1000 IU if obese)</li> </ul>	Initiate when 25(OH)D levels are below 30 ng/mL based on risk factors. Refer to <a href="#">Vitamin D Deficiency Clinical Pathway</a> for details.	<ul style="list-style-type: none"> <li>• Consider increased supplementation in patients with at-risk medical conditions.</li> <li>• Dosing amount should be inclusive of all supplements (i.e., Vitamin D, multivitamin, Omega-3, etc.).</li> <li>• For the most current recommendations on Vitamin D supplementation, please refer to the <a href="#">Vitamin D Deficiency Clinical Pathway</a>.</li> </ul>
<b>Thiamine [Green book]</b>	IM/IV: 10-25 mg/dose daily PO: 10-50 mg/dose orally every day for 2 weeks, then 5-10 mg/dose orally daily for 1 month	Initiate in patients with severe malnutrition at risk for <a href="#">refeeding syndrome</a>	Give thiamine IV/IM for critically ill patients with malnutrition/FTT.

## REFEEDING SYNDROME

### Risk factors

- Patients with marasmus or Kwashiorkor particularly if there is greater than 10% weight loss over a couple of months
- Patients who are not fed for 7-10 days with evidence stress and depletion

### Features [12, 13]

- Abnormalities of fluid balance and electrolytes (low potassium, low phosphorus, low magnesium)
- Abnormalities of glucose metabolism (high glucose, high insulin level)

### Treatment

- When electrolytes abnormalities occur, hold off the advancement of feed to correct
- For enteral dosing recommendations, refer to [Table 4](#). For IV electrolyte replacement recommendations please refer to the [Intravenous Fluid Therapy Clinical Care Guideline](#).

### Monitoring

- Check refeeding labs (magnesium, potassium, phosphorus) one or twice a day for 4 days. The risk of refeeding syndrome is minimal after 4 days of feeding.

**Table 4. Enteral Electrolyte Replacement**

**Note: For IV replacement, please refer to the [Intravenous Fluid Therapy clinical pathway](#)**

Electrolyte	Enteral Dosing Recommendations	Clinical Pearls	Formulations
<b>Phosphorus</b>	2-3 mMol/kg/day divided three or four times daily.  Adult dose: 50-150 mMol/day divided three or four times daily.	1 mmol =31 mg  Enteral phosphorus replacement can be given as a sodium salt, potassium salt, or a combination of both salt forms	<b><u>K-phos neutral:</u></b> 8 mmol phos, 13 mEq Na, 1.1 mEq K per tab  <b><u>Phos-NaK powder:</u></b> 8 mmol phos, 6.9 mEq Na, 7.1 mEq K per packet  <b><u>Sodium Phosphate:</u></b> 3 mmol phos, 4 mEq Na per mL  <b><u>Potassium Phosphate:</u></b> 3 mmol phos, 4.4 mEq K per mL
<b>Magnesium</b>	PO: 10-20 mg/kg/dose <b>elemental</b> magnesium 4 times/day  Adult dose: 300 mg <b>elemental</b> magnesium 4 times daily	Separate from phosphorus supplementation 1-2 hours to ensure maximal absorption.	<b><u>Magnesium Oxide 140 mg cap=</u></b> 84.5 mg elemental Magnesium,  <b><u>Magnesium Hydroxide</u></b> 500 mg elemental magnesium per 15 mL,  <b><u>Magnesium Gluconate</u></b> 54 mg elemental magnesium per 5 mL
<b>Potassium</b>	PO: 2-5 mEq/kg/day in 2-4 divided doses  Adult: 40-100 meQ/day in 2-4 divided doses	Liquid formulations should be diluted to minimize gastric irritation. Take tabs/caps with a full glass of water. Max single dose: 20-25 mEq	<b><u>Potassium Chloride liquid:</u></b> 20 mEq/15 mL (10%) or 40 mEq/15 mL (20%)  <b><u>KCL Extended Release Caps:</u></b> 8 or 10 mEq caps (also available in sprinkle cap)  <b><u>KCL Extended Release Tabs:</u></b> 8, 10, 15, or 20 mEq tabs

### DISCHARGE

Literature review did not yield evidence based criteria for discharge readiness. It is our group consensus to consider the following factors in addition to the patient demonstrating weight gain in the hospital:

- Caregiver should demonstrate ability to provide responsive feeding and understanding of hunger and satiety cues.
- Caregiver should demonstrate mastery of preparing formula using the teach-back method.
- Room in for 24 hours and providing all feeds with no assistance from staff is essential to ensure the plan is practical for post discharge.
- Follow up is planned with either Growth and Parenting (GAP) clinic or PCP within 2-5 days from discharge.

### RELATED DOCUMENTS

- [Vitamin D Deficiency clinical pathway](#)
- [Intravenous Fluid Therapy clinical pathway](#)
- [Nutrition Screening, Assessment, and Reassessment Policy](#)
- [Naso/Orogastic Tubes: Education for Outpatient Nasogastric Tube Placement](#)
- [Parent/Family Nutrition Handouts](#)



### APPENDIX A. WORKUP FOR SUSPECTED INBORN ERROR OF METABOLISM/GENETICS [5]

When to consider inborn error of metabolism:

- History of acute life threatening symptoms like ketoacidosis and hypoglycemia
- Recurrent attacks of vomiting, lethargy and diarrhea
- Liver dysfunction
- Developmental delay, hypotonia, stroke, ataxia
- Cardiomyopathy, myopathy
- Hearing loss or visual impairment
- Organomegaly
- Dysmorphic features
- Pancytopenia

Plan: metabolic consult, labs to consider:

- Serum amino acids
- Plasma acycarnitine
- Ammonia
- Blood Lactate, pyruvate
- CK
- Urine organic acids.

### APPENDIX B. CONSIDERATIONS FOR CYSTIC FIBROSIS/PANCREATIC INSUFFICIENCY: UNDERSTANDING THE NEWBORN SCREEN [6]

- The newborn screen (NBS) identifies infants at risk for CF by screening for hypertrypsinogenemia. Next then the CF transmembrane conductance regulator gene (CFTR) is interrogated for mutations.
- Individuals identified by the newborn screen are diagnosed with CF if they have an elevated sweat chloride level, or they have inherited 2 disease causing mutations in the CFTR gene.
- Not all CFTR mutations are disease causing. The term CFTR-related metabolic syndrome (CRMS) refers to infants identified on the newborn screen who have normal sweat chloride test, and up to 2 mutations in the CFTR gene, at least 1 of them not a “CF causing mutation”
- Infants with CRMS can be totally asymptomatic. However they can also present with poor weight gain due to pancreatic insufficiency. Other symptoms include recurrent sinus infections, wheezing, and recurrent diarrhea.
- Our approach: check fat in stool when considering CF or CRMS as a cause for poor growth.

**APPENDIX C. ESTIMATED ENERGY NEEDS FOR PEDIATRIC PATIENTS**

Age	Range of energy needs (Kcal/kg/day)
Preterm	110-130
Term 0-6 months	90-120
7-12 months	90-120
1-3 years	75-100
4-6 years	65-90
7-10 years	55-70
11-14 years	40-55
15-18 years, males	40-55
15-18 years, females	30-40
Adult	25-35

**APPENDIX D: CATCH UP GROWTH CALCUATIONS**

In cases of severe malnutrition where growth may take a long period of time, these calculations can be useful in consultation with the registered dietician (RD):

- Consider the total weight deficit and the amount of time desired to achieve ideal body weight (IBW).
- The energy cost of each gram of new growth is 5 Kcal [14].
- Patients 2 or younger: Total Kcal/kg/day needed = (RDA Kcal/kg based on weight age×IBW)÷actual weight [15].
- Patients older than 2: *Extra* Kcal/kg/day needed= [weight deficit (g)×5] ÷ days to correct.

**APPENDIX E. ICD 10 CODES**

ICD-10 description	ICD-10 code
Severe protein energy malnutrition	E43
Moderate protein energy malnutrition	E44.0
Mild protein energy malnutrition	E44.1

## REFERENCES


1. in *Guideline: Updates on the Management of Severe Acute Malnutrition in Infants and Children*. 2013: Geneva.
2. Duggan, C., J.B. Watkins, and W.A. Walker, *Nutrition in pediatrics : basic science, clinical application*. 4th ed. 2008, Hamilton: BC Decker. xvii, 923 p.
3. Waterlow, J.C., *Classification and definition of protein-calorie malnutrition*. Br Med J, 1972. **3**(5826): p. 566-9.
4. Becker, P., et al., *Consensus statement of the Academy of Nutrition and Dietetics/American Society for Parenteral and Enteral Nutrition: indicators recommended for the identification and documentation of pediatric malnutrition (undernutrition)*. Nutr Clin Pract, 2015. **30**(1): p. 147-61.
5. Daniel, M., L. Kleis, and A.P. Cemeroglu, *Etiology of failure to thrive in infants and toddlers referred to a pediatric endocrinology outpatient clinic*. Clin Pediatr (Phila), 2008. **47**(8): p. 762-5.
6. Ficicioglu, C. and K. An Haack, *Failure to thrive: when to suspect inborn errors of metabolism*. Pediatrics, 2009. **124**(3): p. 972-9.
7. Cystic Fibrosis, F., et al., *Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond*. J Pediatr, 2009. **155**(6 Suppl): p. S106-16.
8. Adedoyin, O., et al., *Evaluation of failure to thrive: diagnostic yield of testing for renal tubular acidosis*. Pediatrics, 2003. **112**(6 Pt 1): p. e463.
9. Hobbs, C. and H.G. Hanks, *A multidisciplinary approach for the treatment of children with failure to thrive*. Child Care Health Dev, 1996. **22**(4): p. 273-84.
10. Fryer, G.E., Jr., *The efficacy of hospitalization of nonorganic failure-to-thrive children: a meta-analysis*. Child Abuse Negl, 1988. **12**(3): p. 375-81.
11. American Academy of Pediatrics. Committee on Nutrition. and L.A. Barness, *Pediatric nutrition handbook*. 6th ed. 2009, Elk Grove Village, IL: American Academy of Pediatrics. xlix, 1470 p.
12. Crook, M.A., V. Hally, and J.V. Panteli, *The importance of the refeeding syndrome*. Nutrition, 2001. **17**(7-8): p. 632-7.
13. Kraft, M.D., I.F. Btaiche, and G.S. Sacks, *Review of the refeeding syndrome*. Nutr Clin Pract, 2005. **20**(6): p. 625-33.
14. Spady, D.W., et al., *Energy balance during recovery from malnutrition*. Am J Clin Nutr, 1976. **29**(10): p. 1073-88.
15. Frank, D.A. and S.H. Zeisel, *Failure to thrive*. Pediatr Clin North Am, 1988. **35**(6): p. 1187-206.

**CLINICAL IMPROVEMENT TEAM MEMBERS**

- Liliane Diab, MD** | Clinical Nutrition
- Nancy Krebs, MD, MS** | Clinical Nutrition
- Jennifer Reese, MD** | Hospitalist
- Emma Ross, PharmD** | Clinical Pharmacist
- Sherry Archuleta, RD** | Clinical Nutrition
- Jillian Nyman, RD** | Clinical Nutrition
- Sarah Nickels, PhD** | Clinical Effectiveness

**APPROVED BY**

- Nutrition Quality Improvement Committee – December 15, 2016
- Clinical Care Guideline and Measures Review Committee – February 14, 2017
- Pharmacy & Therapeutics Committee – March 9, 2017

<b>MANUAL/DEPARTMENT</b>	Clinical Care Guidelines/Quality
<b>ORIGINATION DATE</b>	March 9, 2017
<b>LAST DATE OF REVIEW OR REVISION</b>	March 9, 2017
<b>APPROVED BY</b>	 Lalit Bajaj, MD, MPH Medical Director, Clinical Effectiveness

**REVIEW | REVISION SCHEDULE**

Scheduled for full review on March 9, 2021

Clinical pathways are intended for informational purposes only. They are current at the date of publication and are reviewed on a regular basis to align with the best available evidence. Some information and links may not be available to external viewers. External viewers are encouraged to consult other available sources if needed to confirm and supplement the content presented in the clinical pathways. Clinical pathways are not intended to take the place of a physician’s or other health care provider’s advice, and is not intended to diagnose, treat, cure or prevent any disease or other medical condition. The information should not be used in place of a visit, call, consultation or advice of a physician or other health care provider. Furthermore, the information is provided for use solely at your own risk. CHCO accepts no liability for the content, or for the consequences of any actions taken on the basis of the information provided. The information provided to you and the actions taken thereof are provided on an “as is” basis without any warranty of any kind, express or implied, from CHCO. CHCO declares no affiliation, sponsorship, nor any partnerships with any listed organization, or its respective directors, officers, employees, agents, contractors, affiliates, and representatives.

**Discrimination is Against the Law.** Children's Hospital Colorado complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Children's Hospital Colorado does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex.

Children's Hospital Colorado provides free aids and services to people with disabilities to communicate effectively with us, such as: Qualified sign language interpreters, written information in other formats (large print, audio, accessible electronic formats, other formats). Children's Hospital Colorado provides free language services to people whose primary language is not English, such as: Qualified interpreters, information written in other languages.

If you need these services, contact the Medical Interpreters Department at 720.777.9800.

If you believe that Children's Hospital Colorado has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Corporate Compliance Officer, 13123 E 16th Avenue, B450, Aurora, Colorado 80045, Phone: 720.777.1234, Fax: 720.777.7257, corporate.compliance@childrenscolorado.org. You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Corporate Compliance Officer is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at [ocrportal.hhs.gov/ocr/portal/lobby.jsf](http://ocrportal.hhs.gov/ocr/portal/lobby.jsf), or by mail or phone at: U.S. Department of Health and Human Services 200 Independence Avenue, SW Room 509F, HHH Building Washington, D.C. 20201 1-800-368-1019, 800-537-7697 (TDD) Complaint forms are available at [www.hhs.gov/ocr/office/file/index.html](http://www.hhs.gov/ocr/office/file/index.html).

Children's Hospital Colorado complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex.

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-720-777-9800.

CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1-720-777-9800.

주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1-720-777-9800 번으로 전화해 주십시오

注意: 如果您使用繁體中文, 您可以免費獲得語言援助服務。請致電1-720-777-9800。

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1-720-777-9800.

ማስታወሻ: የሚናገሩት ቋንቋ አማርኛ ከሆነ የትርጉም አርዳታ ድርጅቶቻችን በነጻ ሊያገዝዎት ተዘጋጅተዋል። ወደ ሚከተለው ቁጥር ይደውሉ 1-720-777-9800 (መስማት ስተሳናቸው።

ملحوظة: إذا كنت تتحدث انكر اللغة، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان. اتصل برقم 720-777-9800-1 (رقم)

ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 1-720-777-9800.

ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 1-720-777-9800.

ध्यान बनू होस्तपाइले नेपाल बोल्लनछ भन तपाइको निम्त भाषा सहायता सवाहरू नःशुल्क रूपमा उपलब्ध छ । फोन गनुहोसरू 1-720-777-9800 ।

PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 1-720-777-9800.

注意事項: 日本語を話される場合、無料の言語支援をご利用いただけます。1-720-777-9800 まで、お電話にてご連絡ください。

Nti: O buru na asu lbo, asusu aka oasu n'efu, defu, aka. Call 1-720-777-9800.